乌苯美司对放射治疗鼻咽癌的辅助治疗  

Ubenimex of supplent role for patient with nasopherynx carcinome tako in radiotherapy.

作　　者：唐新生[1] 徐晓薇[1] 段恒英[1] 谭兵[1] 李平[2] 

机构地区：[1]重庆市肿瘤医院,400030 [2]华西医科大学附属第一医院,610041

出　　处：《现代医药卫生》2002年第4期277-278,共2页Journal of Modern Medicine & Health

摘　　要：目的 :评价乌苯美司对放射治疗鼻咽癌患者的辅助治疗作用。方法 :将接受放射治疗的85例病例以3:2的比例随机分为两组。试验组放疗加口服乌苯美司胶囊 ,对照组单纯放疗。观察两组的长期生存率 ,肿瘤的远地转移率和免疫机能变化情况。结果 :两组的5年生存率统计学差异无显著意义 ;两组的肿瘤远地转移率统计学差异有显著意义 ;治疗前后的免疫机能改善 ,试验组有显著意义 ,对照组无显著意义。结论 :乌苯美司对放射治疗的鼻咽癌患者有辅助治疗作用 。Objective:Estimato Ubenimex of supplement role for patient with nasopharynx carcinoma take in radiotherapy.Methods:85 patients with nasopharynx squamous carcinoma take in radiotherapy were randomized into two groups,51 pationts into test group with radiotherapy plus take orally Ubenimex capsule,34 patients into comparison group with radiotherapy alone.Observed the long-term survival rates,the tumor metastasis rates and the change of immunity enginery of the two groups.Results:There were not evident differences of 5 year survivals among radiotherapys plus take orally Ubenimex capsule and radiotherapy alone;There were evident differences in the change of immunity enginery for test group and were not for comparison group.Conclusions:Ubenimex can play a supplement role for patient with nasopharynx carcinoma take in radiotherapy.But it is necessary to enlarge observe quantity of patients.

关 键 词：乌苯美司 放射治疗 鼻咽癌 辅助治疗 免疫机能 

分 类 号：R739.63[医药卫生—肿瘤] R730.5[医药卫生—临床医学]